Crowdonomics
All companies

Bioquest Corp

Public

Biotech · Newport Beach, CA

Estimated pre-money ⓘ
$16.2M
As of Oct 2020 · from Reg A Offering (2020-10-21) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$395,300
Crowd $112K · Private $283K · 6 rounds since 2020
Latest share price
$2.00
Private · Common Stock · Jul 2020 offering price

Financials

FY2013–FY2023 (no data for FY2015, FY2016, FY2017) · from SEC filings · hover any figure for its source
$0
−$8K
2013
$0
−$488K
2014
2015no data
2016no data
2017no data
$0
−$241K
2018
$0
−$359K
2019
−$359K
2020
−$2.3M
2021
−$821K
2022
$0
−$123K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2013 audited
FY2014 audited
FY2018
FY2019
FY2020 audited
FY2021 audited
FY2022 audited
FY2023
Income statement
Revenue
$0
$0
$0
$0
—
—
—
$0
Cost of goods sold
—
—
$0
$0
—
—
—
$0
Net income
-$8,277
-$487,992
-$241,153
-$359,029
-$359,029
-$2,323,962
-$821,022
-$123,328
Taxes paid
$0
$0
—
—
—
—
—
—
Balance sheet
Cash
$7,978
$543,853
$34,727
$166
$166
$260
$33,540
$5,914
Accounts receivable
—
—
$0
$0
—
—
—
$0
Total assets
$9,124
$889,903
$347,272
$166
$166
$17,097
$33,540
$5,914
Long-term debt
—
—
$35,000
$40,000
—
—
—
$0
Total liabilities
$101
$14,700
$41,430
$138,745
$138,745
$1,786,638
$466,530
$632,896
Other
Headcount
—
—
0
6
—
—
—
0

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$16.1M
est. pre-money
$16.1M
est. pre-money
$16.2M
est. pre-money
$11.5M
est. pre-money
Private · Common · Jul 2020
Reg A+ · Equity · Feb 2020
Reg A+ · Equity · Oct 2020
Reg A+ · Equity · May 2024

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Share price over rounds

$2.00$1.00$2.00
Feb 2020Jul 2020
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Jul 26, 2024
ClassOutstandingVotes / shareShare of totalLast price
Common Stock, $.001 par value11,485,230—100.0%$2.00Jul 2020

Shares outstanding over timein today's share terms

204M102M0
Apr 2014Apr 2024
Common Stock, $.001 par valueRound openedSplit / conversion

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $0 / $10MEst. pre-money $11.5M
Raised $0 / $5MEst. pre-money $16.2M
Raised $112K / $1MEst. pre-money $16.1M
Raised $100KEst. pre-money $16.1M

Team

6 people
Thomas Hemingway
CEO and Director
David Noyes
CFO
Michael Krall
President, COO and Director
Jeffery Donnell
Operations and Director
Corinda J. Melton
Director
Robert Orbach
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 253G2Oct 8, 20240001493152-24-040421
    EDGAR
  • Form 1-UAug 28, 20240001493152-24-034100
    EDGAR
  • Form QUALIFAug 21, 20249999999994-24-000133
    EDGAR
  • Form 1-A/AJul 26, 20240001493152-24-029162
    EDGAR
  • Form 1-A/AJul 1, 20240001493152-24-025703
    EDGAR
  • Form 1-AMay 15, 20240001493152-24-019717
    EDGAR
  • Form 1-ZApr 17, 20240001493152-24-014999
    EDGAR
  • Form 10-QSep 12, 20220001493152-22-025605
    EDGAR
Source: SEC EDGARCIK 0001568628NVShare price $1.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.